NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

European Registry of Next Generation Imaging in Advanced Prostate Cancer

RecruitingN/A

Sponsor: Fundacio Puigvert

Conditions: Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Interventions: Imaging

Countries: Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Sweden

The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form. Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adult male patients (≥18 years with no upper age limit).
2. Histologically proven prostate cancer.
3. Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
4. Patients who authorize their participation in the study by signing a written informed consent form (ICF).

Exclusion Criteria:

1. Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
2. Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
3. Patients who will not be able to complete the study.

Locations (24)

Leuven, Belgium
Lille, France
Lyon, France
Paris, France
Bonn, Germany
Hamburg, Germany
Munich, Germany
Planegg, Germany
Tübingen, Germany
Bologna, Italy
Florence, Italy
Florence, Italy
Milan, Italy
Rotterdam, Netherlands
Krakow, Poland
Barcelona, Spain
Barcelona, Spain
Córdoba, Spain
Madrid, Spain
Madrid, Spain
San Cristóbal de La Laguna, Spain
Santander, Spain
Santiago de Compostela, Spain
Malmö, Sweden